TCM
APGE icon

Tang Capital Management’s Apogee Therapeutics APGE Stock Holding History

Tang Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,000
Closed -$7.95M – 82
2025
Q3 		$7.95M Hold
200,000
– – 0.31% 73
2025
Q2 		$8.69M Hold
200,000
– – 0.44% 59
2025
Q1 		$7.47M Buy
200,000
+100,000
+100% +$3.87M 0.41% 58
2024
Q4 		$4.53M Hold
100,000
– – 0.3% 76
2024
Q3 		$5.87M Hold
100,000
– – 0.42% 68
2024
Q2 		$3.94M Hold
100,000
– – 0.4% 66
2024
Q1 		$6.64M Buy
+100,000
New +$4.37M 0.69% 49

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Tang Capital Management's APGE Position: Q4 2025 in Review

Tang Capital Management sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 200,000 shares — an estimated $7.95M sold.

Tang Capital Management first reported a position in APGE in Q1 2024 and held it in 7 quarters. The position peaked at $8.69M in Q2 2025. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • Tang Capital Management reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 200,000 Apogee Therapeutics shares in Q4 2025, an estimated $7.95M.
  • Tang Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and held it in 7 quarters.
  • Tang Capital Management's Apogee Therapeutics position peaked at $8.69M in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.